Across TCGA pan-cancer cohorts, MIR5739 RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of MIR5739’s most consistent transcriptional readouts.
The strongest signal is observed in breast invasive carcinoma (BRCA), where MIR5739 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types MIR5739 is over-expressed in tumor, although a few such as STAD show the opposite, repressed pattern.
BRCA and STAD are the cancer types where MIR5739 tumor–normal differential expression is most reproducible.